Brokerages Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Price Target at $51.33

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been assigned an average rating of “Hold” from the six research firms that are presently covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $52.50.

A number of equities analysts recently weighed in on the stock. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $46.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, June 13th. Royal Bank of Canada reiterated an “outperform” rating and issued a $55.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, September 19th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Friday, September 20th. The Goldman Sachs Group lifted their price objective on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a “neutral” rating in a research report on Tuesday, June 4th. Finally, StockNews.com lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, August 5th.

Agios Pharmaceuticals Trading Down 4.4 %

Shares of AGIO opened at $42.47 on Friday. The firm has a market cap of $2.41 billion, a PE ratio of -6.72 and a beta of 0.75. The company’s 50 day simple moving average is $45.47 and its 200-day simple moving average is $40.01. Agios Pharmaceuticals has a 12-month low of $19.80 and a 12-month high of $53.28.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The business had revenue of $8.60 million for the quarter, compared to analysts’ expectations of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The business’s revenue was up 28.4% on a year-over-year basis. During the same quarter last year, the business posted ($1.51) earnings per share. As a group, equities research analysts forecast that Agios Pharmaceuticals will post -4.85 EPS for the current fiscal year.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the firm’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the sale, the chief financial officer now owns 20,158 shares of the company’s stock, valued at $988,346.74. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, CEO Brian Goff sold 11,091 shares of Agios Pharmaceuticals stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the transaction, the chief executive officer now owns 78,792 shares of the company’s stock, valued at approximately $3,368,358. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the transaction, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. The disclosure for this sale can be found here. 4.93% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Acadian Asset Management LLC acquired a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth $37,000. Quest Partners LLC acquired a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth $40,000. North Star Asset Management Inc. acquired a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth $216,000. XTX Topco Ltd acquired a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth $230,000. Finally, Northcape Wealth Management LLC acquired a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth $244,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.